A Phase 4 interventional study of tasimelteon 20 mg capsule and tasimelteon 2 mg I.V. in Non-24-Hour-Sleep-Wake Disorder, sponsored by Vanda Pharmaceuticals. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-22.
Sponsored by Vanda Pharmaceuticals · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Hetlioz™ (tasimelteon) is used in the treatment of Non-24-Hour-Sleep-Wake Disorder (Non-24). Non-24 is very common in people who are totally blind because light can not reset their body clock. This causes the internal sleep-wake cycle to be out of sync with the 24-hour day-night. Non-24 is a serious, chronic circadian rhythm disorder in the blind that causes nighttime sleep problems and a wide range of daytime difficulties, including an overwhelming urge to nap.
Tasimelteon will be given in two ways; orally (by mouth) as a 20 mg capsule and intravenously (I.V.) by infusion through a catheter (not an injection) into a vein. The oral administration is approved by the FDA. The I.V. administration is considered investigational as it has not been approved by the FDA. This will be the first time tasimelteon will be given to humans by intravenous (I.V.) injection.
The purposes of this research study are to:
Pharmacokinetics (PK) is the study of how a drug is absorbed, distributed, metabolized, and eventually eliminated by the body. Pharmacokinetics is what the body does to the drug. Blood samples will be taken throughout the study for PK analysis.
135 studies on the registry are indexed under Sleep Disorders, Circadian Rhythm; 25 are open to participants now.
This study's enrollment of 14 is below the median of 59 across 102 interventional studies indexed under Sleep Disorders, Circadian Rhythm.
Browse Sleep Disorders, Circadian Rhythm studies →Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Vital signs (after 3 minutes resting in a semi-supine position) which are within the ranges shown below:
Exclusion Criteria:
History of porphyria or liver disease and/or positive for one or more of the following serological results:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Single oral dose of tasimelteon 20 mg on Day 1 * Single I.V. dose of tasimelteon 2 mg on Day 6
Drug: tasimelteon 20 mg capsule · Drug: tasimelteon 2 mg I.V.
* Single I.V. dose of tasimelteon 2 mg on Day 1 * Single oral dose of tasimelteon 20 mg on Day 6
Drug: tasimelteon 20 mg capsule · Drug: tasimelteon 2 mg I.V.
Also known as: Hetlioz™ 20 mg
Absolute Bioavailability After a Single Oral Dose of Hetlioz™(Tasimelteon) 20mg
The absolute bioavailability (F) of tasimelteon will be estimated from the dose-corrected AUC(inf) after oral and I.V. administration using an analysis of variance (ANOVA) model with treatment, period, sequence, and subject within sequence as the classification variables, using natural log-transformed data. The geometric mean ratio (GMR), oral-to-I.V., and its associated 90% confidence interval (CI) will be used as the estimate of F and its variability.
Time frame: pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose
Cmax of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.
Cmax of tasimelteon will be compared when given orally or administered as an I.V.
Time frame: pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose
AUC (Inf) of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.
AUC (inf) of Tasimelteon will be compared when given orally or administered as an I.V.
Time frame: pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose
T1/2 of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.
T1/2 of tasimelteon will be compared when given orally or administered as an I.V.
Time frame: pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours pos-dose
Total Clearance of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration.
CL of tasimelteon will be compared when given orally or administered as an I.V.
Time frame: pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose
Cmax of Tasimelteon's Metabolites After an Oral and I.V. Dose of Tasimelteon
The mean +/- SD for the Cmax of tasimelteon's metabolites after a single 20 mg oral dose of tasimelteon and after a single 2 mg I.V. administration of tasimelteon
Time frame: pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose
AUC(Inf) of Tasimelteon's Metabolites After a Single Oral and I.V. Dose
The mean +/- SD for the AUC(inf) of tasimelteon's metabolites after a single 20 mg oral dose of tasimelteon and after a single 2 mg I.V. administration of tasimelteon
Time frame: pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose
Metabolite-to-parent AUC(Inf) Ratios After Oral Administration of a Single 20 mg Dose and IV Administration of a Single 2 mg Dose of Tasimelteon
Comparison of the metabolite-to-parent AUC(inf) ratios for the oral and IV routes.
Time frame: pre-dose, -0.125, 0, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose
Number of Participants With Adverse Events
Number of participants with treatment-emergent adverse event per treatment arm and overall.
Time frame: From Baseline to End of Study; Day 5 (± 2 days).
Number of Participants That Reported Suicidal Ideation, Suicidal Behavior, or Suicide Attempts.
Number of Participants that reported suicidal ideation, suicidal behavior, or suicide attempts per treatment arm and overall.
Time frame: Baseline to End of Study Day 5 (± 2 days).
| Milestone | Sequence A | Sequence B |
|---|---|---|
| Started | 6 | 8 |
| Completed | 6 | 8 |
| Not completed | 0 | 0 |
The absolute bioavailability (F) of tasimelteon will be estimated from the dose-corrected AUC(inf) after oral and I.V. administration using an analysis of variance (ANOVA) model with treatment, period, sequence, and subject within sequence as the classification variables, using natural log-transformed data. The geometric mean ratio (GMR), oral-to-I.V., and its associated 90% confidence interval (CI) will be used as the estimate of F and its variability.
| Geometric Mean Ratio (%) | Absolute Bioavailability |
|---|---|
| Absolute Bioavailability After a Single Oral Dose of Hetlioz™(Tasimelteon) 20mg | 38.3 (26.9 to 54.3) |
Cmax of tasimelteon will be compared when given orally or administered as an I.V.
| ng/mL | Oral (20 mg) | IV (2 mg) |
|---|---|---|
| Cmax of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration. | 260 ± 189 | 82.2 ± 20.5 |
AUC (inf) of Tasimelteon will be compared when given orally or administered as an I.V.
| (h*ng/mL) | Oral (20 mg) | IV (2 mg) |
|---|---|---|
| AUC (Inf) of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration. | 358 ± 271 | 71.6 ± 23.9 |
T1/2 of tasimelteon will be compared when given orally or administered as an I.V.
| hour | Oral (20 mg) | IV (2 mg) |
|---|---|---|
| T1/2 of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration. | 1.06 ± 0.23 | 1.02 ± 0.23 |
CL of tasimelteon will be compared when given orally or administered as an I.V.
| (mL/min) | Oral (20 mg) | IV (2 mg) |
|---|---|---|
| Total Clearance of Tasimelteon After a Single 20 mg Oral Dose and After a Single 2 mg I.V. Administration. | 2241 ± 3592 | 505 ± 135 |
The mean +/- SD for the Cmax of tasimelteon's metabolites after a single 20 mg oral dose of tasimelteon and after a single 2 mg I.V. administration of tasimelteon
| ng/mL | Oral (20 mg) | IV (2 mg) |
|---|---|---|
| M9 | 303 ± 94.3 | 16.4 ± 6.16 |
| M11 | 53.2 ± 16.14 | 3.7 ± 1.25 |
| M12 | 113 ± 30.8 | 7.31 ± 2.49 |
| M13 | 370 ± 105 | 29 ± 11.7 |
The mean +/- SD for the AUC(inf) of tasimelteon's metabolites after a single 20 mg oral dose of tasimelteon and after a single 2 mg I.V. administration of tasimelteon
| h*ng/mL | Oral (20 mg) | IV (2 mg) |
|---|---|---|
| M9 | 400 ± 139 | 30.3 ± 10.3 |
| M11 | 125 ± 43.7 | 12.2 ± 4.40 |
| M12 | 619 ± 364 | 43.8 ± 25.4 |
| M13 | 431 ± 152 | 38.2 ± 13 |
Comparison of the metabolite-to-parent AUC(inf) ratios for the oral and IV routes.
| metabolite to parent AUC (inf) ratios | Oral (20 mg) | IV (2 mg) |
|---|---|---|
| M9 | 1.98 ± 2.65 | 0.39 ± 0.12 |
| M11 | 0.51 ± 0.35 | 0.16 ± 0.03 |
| M12 | 2.04 ± 0.93 | 0.54 ± 0.15 |
| M13 | 1.72 ± 1.12 | 0.51 ± 0.14 |
Number of participants with treatment-emergent adverse event per treatment arm and overall.
| participants | Tasimelteon 20mg Oral | Tasimelteon 2mg IV | All Subjects |
|---|---|---|---|
| vomiting | 0 | 1 | 1 |
| headache | 1 | 1 | 2 |
| Somnolance | 1 | 0 | 1 |
Number of Participants that reported suicidal ideation, suicidal behavior, or suicide attempts per treatment arm and overall.
| participants | Tasimelteon 20mg Oral | Tasimelteon 2mg IV | All Subjects |
|---|---|---|---|
| Number of Participants That Reported Suicidal Ideation, Suicidal Behavior, or Suicide Attempts. | 0 | 0 | 0 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tasimelteon 20mg Oral | — | 0/14 (0%) | 2/14 (14.3%) |
| Tasimelteon 2mg IV | — | 0/14 (0%) | 1/14 (7.1%) |
| All Subjects | — | 0/14 (0%) | 3/14 (21.4%) |
| Event | Tasimelteon 20mg Oral | Tasimelteon 2mg IV | All Subjects |
|---|---|---|---|
| headacheNervous system disorders | 1/14 | 1/14 | 2/14 |
| sommolenceNervous system disorders | 1/14 | 0/14 | 1/14 |
| vomitingGastrointestinal disorders | 0/14 | 1/14 | 1/14 |
| Age, Continuous(years) | Overall Number of Baseline Participants |
|---|---|
| Mean | 31.2 ± 10.6 |
| Sex: Female, Male(Participants) | Overall Number of Baseline Participants |
|---|---|
| Female | 7 |
| Male | 7 |
| Ethnicity (NIH/OMB)(Participants) | Overall Number of Baseline Participants |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 14 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Overall Number of Baseline Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 6 |
| White | 8 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Overall Number of Baseline Participants |
|---|---|
| United States | 14 |
| Body Mass Index((kg/m^2)) | Overall Number of Baseline Participants |
|---|---|
| Mean | 22.8 ± 1.8 |
| Weight((kg)) | Overall Number of Baseline Participants |
|---|---|
| Mean | 63.6 ± 8 |
| Height((cm)) | Overall Number of Baseline Participants |
|---|---|
| Mean | 166.6 ± 10.4 |
No study locations are listed for this record.
The record gives a start of May 2014, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2016, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tasimelteon
Sleep Disorders, Circadian Rhythm →